4//SEC Filing
Jones David Scott 4
Accession 0001562180-24-001050
CIK 0001314102other
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 5:15 PM ET
Size
8.8 KB
Accession
0001562180-24-001050
Insider Transaction Report
Form 4
Jones David Scott
SVP & Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2024-02-02$11.47/sh+209$2,397→ 38,171 total - Sale
Common Stock
2024-02-02$28.49/sh−209$5,954→ 37,962 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-02-02−209→ 4,375 totalExercise: $11.47Exp: 2031-11-01→ Common Stock (209 underlying)
Footnotes (1)
- [F1]The option to purchase vests and becomes exercisable as follows: 25% at November 1st, 2022 and the remainder ratably, on a monthly basis, over the remaining three years.
Documents
Issuer
EyePoint Pharmaceuticals, Inc.
CIK 0001314102
Entity typeother
Related Parties
1- filerCIK 0001779458
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 5:15 PM ET
- Size
- 8.8 KB